Skip to content

Advertisement

Malaria Journal

Featured article

Adjunctive therapy for severe malaria: a review and critical appraisal

Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the outcomes achieved with specific anti-malarial therapy. In the last decades, several interventions targeting different pathways have been tested. However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and other candidate therapeutics that may be evaluated in future clinical trials.

Articles

View all articles
View all articles

2018

Thematic series
Time to go for vivax
Edited by: Marcus V Lacerda and Hernando A del Portillo

2017

Thematic series
ACT now: anti-malarial market complexity one decade after the introduction of artemisinin combination therapy – evidence from sub-Saharan Africa and the Greater Mekong Sub-region

Thematic series

Ivermectin to reduce malaria transmission

2016

Thematic series
Housing and malaria
Edited by: Dr. Lucy Tusting, Dr. Jo Lines and Barbary Willey

2015

Thematic series
Re-imagining malaria – a platform for reflections to widen horizons in malaria control
Edited by: Dr. Julian Eckl, Dr. Susanna Hausmann Muela

Cross journal collection
Every day is Malaria Day

2014

Cross journal collection
Reviewer acknowledgements 2013

2012

Thematic series
WHO global malaria recommendations 2012 - 2015

2011

Thematic series
The ACTwatch project: monitoring anti-malarial markets in seven countries

Thematic series
Travellers' malaria
Edited by: Prof Patricia Schlagenhauf

2010

Thematic series
National malaria control programme (NMCP) Best Practice Sharing
Edited by: Prof Robert William Snow

Thematic series
Towards malaria elimination

2007

Thematic series
The world antimalarial resistance network (WARN)

Aims and Scope

Malaria Journal is aimed at the scientific community interested in malaria in its broadest sense. It is the only journal that publishes exclusively articles on malaria and, as such, it aims to bring together knowledge from the different specialties involved in this very broad discipline, from the bench to the bedside and to the field. Malaria Journal offers a fast publication schedule while maintaining rigorous peer-review; this is achieved by managing the whole of the publication process electronically, from submission to peer-review.

Editor-in-Chief - Marcel Hommel, University of Liverpool, UK

Latest Tweets

Latest collections

ACT now: anti-malarial market complexity one decade after the introduction of artemisinin combination therapy – evidence from sub-Saharan Africa and the Greater Mekong Sub-region

ACTwatch report on their 10-year monitoring of ACT usage in sub-Saharan Africa and in the Greater Mekong sub- region, make recommendations and share their data with the malaria community. They have spoken to BugBitten about their work and their motivation for making their datasets publicly available.

Ivermectin to reduce malaria transmission

Ivermectin has been used to treat some NTDs for years, but its potential use to block malaria transmission is not well known. Carlos Chaccour and colleagues review the role the ivermectin can play in reducing malaria. Carlos Chaccour and Regina Rabinovich also discuss the series and ivermectin in their interview with BugBitten blog.

Advertisement

logo

2016 Journal Metrics

Advertisement